

Natco Pharma Limited

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243
CIN: L24230TG1981PLC003201, www.natcopharma.co.in

June 25, 2019

The Manager - CRD M/s. BSE Limited Dalal Street, Fort <u>Mumbai 400 001</u> Scrip Code: 524816 The Manager - Listing
M/s. National Stock Exchange of India Ltd
Exchange Plaza, Bandra Kurla Complex,
Bandra (E) <u>Mumbai 400 051</u>

Scrip Code: NATCOPHARM

Dear Sir,

Sub: Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Pursuant to Regulation 23(9) of the SEBI (LODR)Regulations, 2015, we are enclosing herewith a disclosure of Related Party Transactions for the the year ended 31st March, 2019.

Kindly take the above on your records

Thanking you,

Yours faithfully,

For NATCO Pharma Limited Phar

M Adinarayana

MANarayouna

Company Secretary &

Vice President (Legal & Corp. Affairs)

NATCO	Pharma Limited	
111100	1 Holling Emilied	
(All amo	ounts in ₹ millions, except share data and where otherwise stated)	
Rel	ated party disclosures, as per Ind AS 24	
(a) Nar	nes of the related parties and nature of relationship	
Nar	nes of related parties	Nature of relationship
NA ⁻	TCO Pharma Inc., United States of America	
	e cap Overseas Limited, Mauritius	
	TCO Pharma (Canada) Inc., Canada	Subsidiary company
	TCO Pharma Asia PTE Ltd., Singapore	, , , , , , , , , , , , , , , , , , , ,
	TCO Pharma Australia PTY Ltd., Australia TCO Lifesciences Philippines Inc., Philippines	
-	cofarma Do Brasil Ltda. Brazil	Step-down subsidiary company
	e Cap Pharma Labs Limited	Entities in which KMP have control or
	TCO Trust	have significant influence
Mr.	V.C.Nannapaneni	
	Rajeev Nannapaneni	
	Sreerama Murthy Gubbala	
_	Govinda Prasad Dasu	
_	Umamaheshwarrao Naidu Madireddi Venkateswara Rao Thallapaka	Key management personnel ("KMP")
	Sridhar Sankararaman	i
	Leela Digumarti	
Mr.	Potluri Prasad Sivaramakrishna	ō .
	Lingarao Donthineni	
	Durga Devi Nannapaneni	Relative of KMP
Dr.	Ramakrishna Rao	
(b) Tra	nsactions with related parties	For the year ended
110	insuctions with related purities	31 March 2019
>> Tra	nsactions with subsidiaries	
	estment in equity shares TCO Pharma Asia PTE Ltd., Singapore	43
	TCO Pharma Australia PTY Ltd., Singapore	24 7
	TCO Lifesciences Philippines Inc., Philippines	12
	are application money pending allotment	2
Tim	e cap Overseas Limited, Mauritius	2
N 1 -		394
	an given ne cap Overseas Limited, Mauritius	165
	TCO Pharma Asia PTE Ltd., Singapore	108
	TCO Pharma Inc., United States of America	114
NA.	TCO Lifesciences Philippines Inc., Philippines	7
	erest on loans ne cap Overseas Limited, Mauritius	14
	TCO Pharma Asia PTE Ltd., Singapore	10
	TCO Pharma Inc., United States of America	2
NA	TCO Lifesciences Philippines Inc., Philippines	C
> Sal	e of products	157
NA NA	TCO Pharma (Canada) Inc., Canada TCO Pharma Asia PTE Ltd., Singapore	150
1373	1 0 0 1 manner (wat i The East, Girligaporo	
>> Tra	insactions with step-down subsidiary	
> Sal	e of products	48
Nat	cofarma Do Brasil Ltda , Brazil	48
>> T.	pagetions with actition where KARD have simplificant in the control of	
>> Tra	insactions with entities where KMP have significant influence	
> Tin	ne Cap Pharma Labs Limited	60
	Sales promotion expenses	6
b) f	Purchase of Land	49
(c) F	Rental expense	5

For NATCO Pharma Limited

5.V.V.N. APPARAO Chief Financial Officer

All amounts in ₹ millions, except share data and where otherwise stated)	For the year ended
	31 March 2019
NATCO Trust	140
a) Donations	24
b) CSR activities	116
> Transactions with KMP	
Short-term employee benefits	61
Mr. V.C. Nannapaneni	17
Mr. Rajeev Nannapaneni	16
Mr. P S R K Prasad	14
Dr Linga Rao	14
Leave encashment paid	3
Mr. V.C. Nannapaneni	
Mr. Rajeev Nannapaneni	1
Mr. P S R K Prasad	0
Dr.Linga Rao	0
Rental expenses	3
Mr. V.C. Nannapaneni	2
Mr. Rajeev Nannapaneni	1
The same of the sa	
Sitting fees	1
Mr. Govinda Prasad Dasu	
Mrs. Leela Digumarti	
Mr. Umamaheshwarrao Naidu Madireddi	
Mr. Sreerama Murthy Gubbala	
Mr Venkateswara Rao Thallapaka	
c) Balances receivable / (payable)	For the year ended
	31 March 2019
Subsidiaries	623
NATCO Pharma Inc., United States of America	116 256
Time cap Overseas Limited, Mauritius	
NATCO Pharma (Canada) Inc., Canada	132
NATCO Pharma Asia PTE Ltd., Singapore	112
NATCO Lifesciences Philippines Inc., Philippines	7
Step-down subsidiary	47
Natcofarma Do Brasil Ltda., Brazil	47
KMP	(4
Mr. V.C. Nannapaneni	(4 (2 (1
Mr. Rajeev Nannapaneni	(1
Mr. P.S.R.K.Prasad	(0
Dr. Linga Rao	(0

For NATCO Pharma Limited

S.V.V.N. APPA RAO Chief Financial Officer